drugset / Trial / NCT03550794

Thiamine as a Renal Protective Agent in Septic Shock

NCT03550794

Phase 2 Completed 95 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.

Timeline

Start
2018-09-04
Primary completion
2022-04-05
Completion
2022-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Thiamine Other / unclassified 200 mg Intravenous